A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2014-10-03
Target enrollment:
Participant gender:
Summary
Radiotherapy (R/T) for locally advanced hepatocellular carcinoma (HCC) is often used in
patient who is not suitable for transarterial chemoembolization (TACE) and other local
therapy, especially in those with portal vein tumor thrombosis (PVTT) caused by tumor cells.
Several previous studies have showed that local R/T is tolerable and can induce a substantial
tumor response in HCC management. In addition, the safety, toxicity and preliminary efficacy
of Lipotecan® (TLC388) has also been proved in patients with terminal malignancy. This study
aims to evaluate the safety, tolerability and efficacy of concomitant Lipotecan® and
radiotherapy in patients with locally advanced HCC and PVTT.